Make US Pharma Great Again!? - Part 1

White Paper

Make US Pharma Great Again!? – Part 2

Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry.This comes ...

Make US Pharma Great Again!? - Part 1

White Paper

Make US Pharma Great Again!? – Part 1

The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his ver ...

Econometric Analysis Of Biopharmaceutical Transfer Pricing

White Paper

Econometric Analysis Of Biopharmaceutical Transfer Pricing

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of ...

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

White Paper

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

The question this commentary asks is simply this – has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceut ...

Patient Claims Versus EHR Data – How To Choose Between The Two?

White Paper

Patient Claims Versus EHR Data – How To Choose Between The Two?

The topics this white paper will review are which dataset is more appropriate for answering certain types of business questions, look at some cases from the academic literature tha ...

Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?

White Paper

Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?

The Great Recession in the U.S. not only marked a period of the longest and by many measures the largest economic downturn since The Great Depression of the 1930’s, but also alte ...

The Relationship Between Drug Price Controls And Patient Health Outcomes

White Paper

The Relationship Between Drug Price Controls And Patient Health Outcomes

No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service r ...

Do You Know The Answers To Your Important Territory Alignment Questions

White Paper

Do You Know The Answers To Your Important Territory Alignment Questions

Do you know the answers to your important territory alignment questions? Or put another way, do you approach answering questions on your territory alignment issues like the blind s ...

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about th ...

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

White Paper

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipelin ...

Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand - Generic Drug Utilization

White Paper

Impact Of State Pharmacy Drug Product Selection Laws On Patient Brand – Generic Drug Utilization

The pharmacy channel has been an under-studied area by drug companies relative to greater focus on physicians, managed care, hospitals, and patients/consumers. This paper sheds emp ...

Commercial Operations Capabilities Excellence And Business Performance

Blog

Commercial Operations Capabilities Excellence And Business Performance

Pharmaceutical companies spend a substantial amount of money on sales & marketing (S&M). One recent article noted the top 10 pharma companies spent $98.3 billion on S&M ...

Biosimilars In The US - Will They Deliver On The Promise?

Blog

Biosimilars In The US – Will They Deliver On The Promise?

Research presented from Mylan Pharmaceuticals at the recently held 2016 annual meeting of the American Society of Clinical Oncology (ASCO) generated excitement within the medical c ...

White Paper

Improve STAR Rating With Analytics Powered Therapy Adherence Strategy

Improving the quality of care and services to patients and enrollees is one of the key imperatives of Affordable Care Act (ACA). Several initiatives and measures have been put in p ...

White Paper

Better Reporting With The IPad

Good reporting is an essential tool for managing your business. This reporting needs to be focused and actionable – focused in that it addresses the key business questions you fa ...

White Paper

Payer Influence On Product Performance In Pharmaceutical Industry

Payers vary in their ability to assert formulary compliance. We will explore how tools and analytics can enable a pharmaceutical manufacturer to assess factors impacting formulary ...

White Paper

Account Based Models In An Institutional Setting

The stakeholders and factors that drive the ultimate prescribing of a medication have shifted considerably since the turn of the century. ...

Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?

White Paper

Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?

The Great Recession in the U.S. not only marked a period of the longest and by many measures the largest economic downturn since The Great Depression of the 1930’s, but also alte ...

Do You Know The Answers To Your Important Territory Alignment Questions

White Paper

Do You Know The Answers To Your Important Territory Alignment Questions

Do you know the answers to your important territory alignment questions? Or put another way, do you approach answering questions on your territory alignment issues like the blind s ...

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about th ...

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

White Paper

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipelin ...

Commercial Operations Capabilities Excellence And Business Performance

Blog

Commercial Operations Capabilities Excellence And Business Performance

Pharmaceutical companies spend a substantial amount of money on sales & marketing (S&M). One recent article noted the top 10 pharma companies spent $98.3 billion on S&M ...

The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”

White Paper

The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”

The last 10-15 years have seen an explosion of articles in major health policy and medical journals advocating severely restricting or banning biopharmaceutical sales rep access to ...

Biosimilars In The US - Will They Deliver On The Promise?

Blog

Biosimilars In The US – Will They Deliver On The Promise?

Research presented from Mylan Pharmaceuticals at the recently held 2016 annual meeting of the American Society of Clinical Oncology (ASCO) generated excitement within the medical c ...

Challenges To Traditional Pharma Incentive Compensation Plan Design

White Paper

Challenges To Traditional Pharma Incentive Compensation Plan Design

Changes in emerging environmental trends facing the pharma industry are requiring companies to rethink different strategic and operational sales force plans that ultimately drive n ...

White Paper

Measuring Sales Rep-Physician Relationship Disruption In Sales Force Optimization

There is a growing importance of maintaining sales rep-physician relationships and accounting for their disruption in sales force optimization and territory alignment analyses. Thi ...

White Paper

Creating An Effective And Motivating IC Plan

Incentive Compensation is one the most important drivers for sales force productivity and effectiveness. Sales teams today continue to form a significant driver of a firm’s topl ...

White Paper

Payer Influence On Product Performance In Pharmaceutical Industry

Payers vary in their ability to assert formulary compliance. We will explore how tools and analytics can enable a pharmaceutical manufacturer to assess factors impacting formulary ...

White Paper

The Agile And Adaptive Sales Territory Alignment

Sales territory structures often suffer from inefficiency. Even with regular territory re-alignments, territories tend to ‘drift’ away from optimum. ...

Commercial Operations Capabilities Excellence And Business Performance

Blog

Commercial Operations Capabilities Excellence And Business Performance

Pharmaceutical companies spend a substantial amount of money on sales & marketing (S&M). One recent article noted the top 10 pharma companies spent $98.3 billion on S&M ...

Biosimilars In The US - Will They Deliver On The Promise?

Blog

Biosimilars In The US – Will They Deliver On The Promise?

Research presented from Mylan Pharmaceuticals at the recently held 2016 annual meeting of the American Society of Clinical Oncology (ASCO) generated excitement within the medical c ...

The Pricing Challenge Of Pharma's Shift To Specialty Medicines

White Paper

The Pricing Challenge Of Pharma’s Shift To Specialty Medicines

The shift to specialty medicines has opened up for pharma companies a wealth of opportunities in addressing unmet medical needs of patients and improve the cost of care. This shift ...

White Paper

Driver Score – The New Paradigm

Of late, telematics as a disruptive technology is rapidly gaining attention in shaping the future. New industries are accepting this revolution and are moving to data-backed decisi ...

White Paper

At Supplier Management Crossroads? – Choose The Right Approach

Of late, regulators have started focusing attention on the way banks and financial institutions are managing the risk in their supplier management programs. ...

White Paper

Deploying K-Nearest Neighbor Modeling Methodologies For Real World Problems

There has been an immense improvement of theory and algorithms in recent times leading to enhancement in computation power. Also, online data availability was never easier than now ...

White Paper

A Mathematical Framework For Privacy Risk

In recent trends, people’s attitude towards the internet has changed tremendously. The willingness and comfort level of people to share and reveal information about themselves an ...

White Paper

Operational Risk Management In Banks

In recent years, more than 100 losses exceeding US$ 100 million have been reported, prompting the regulators to turn their focus towards effectiveness of Operational Risk Managemen ...

White Paper

Basel Downturn – Identification & Estimation

As part of Basel accords, banks and other financial institution should hold sufficient capital to buffer against large unexpected losses. Minimum capital required, for pillar 1, is ...

White Paper

Borrower Centrism- Bring ‘Service’ Back Into Mortgage Servicing

Mortgage Servicers are entrusted with almost all vital operations, ranging from payment collection to loss mitigation attempts. However, until January 2014, no strict regulations w ...

White Paper

Behavioural Segment Based Stress Testing Using Markov Chain

Stress testing involves assessing a bank’s ability to stay solvent in case of ‘stressed’ macro-economic scenarios. Banks are expected to create a response mechanism in case a ...

White Paper

Evolution Of SDLC

Today, more than ever before, success or failure of a banking enterprise abides a direct correlation towards its ability to meet the demanding time to market conditions. ...